Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
GH GH Guardant Health, Inc. FY ended Feb 13, 2026 | $164.41 | $22.06B | $22.47B | $982.02M | -$375.16M | -$416.28M | -49.52x | 22.47x | — |
NT NTRA Natera, Inc. FY ended Feb 20, 2026 | $320.76 | $46.24B | $46.07B | $2.31B | -$223.62M | -$208.16M | -211.03x | 20.05x | — |
NE NEO NEOGENOMICS INC FY ended Feb 13, 2026 | $17.45 | $2.24B | $2.44B | $727.33M | -$35.54M | -$108.03M | -436.25x | 3.08x | — |
OP OPK OPKO HEALTH, INC. FY ended Jan 30, 2026 | $1.52 | $1.13B | $849.37M | $606.88M | -$136.30M | -$225.68M | -5.07x | 1.87x | — |
LH LH LABCORP HOLDINGS INC. FY ended Feb 23, 2026 | $327.61 | $26.57B | $31.51B | $13.95B | $2.00B | $876.50M | 31.32x | 1.90x | 14.29x |
DG DGX QUEST DIAGNOSTICS INC FY ended Feb 02, 2026 | $236.22 | $26.07B | $30.85B | $11.04B | $2.04B | $992.00M | 27.00x | 2.36x | 13.30x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 13.42x | 2/6 | -$1.38B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 8.62x | 6/6 | $28.00B | $146.67 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -107.26x | 6/6 | $22.30B | $116.84 | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
GH GH Guardant Health, Inc. FY ended Feb 13, 2026 | $164.41 | $22.06B | $22.47B | $982.02M | -$375.16M | -$416.28M | -49.52x | 22.47x | — |
NT NTRA Natera, Inc. FY ended Feb 20, 2026 | $320.76 | $46.24B | $46.07B | $2.31B | -$223.62M | -$208.16M | -211.03x | 20.05x | — |
NE NEO NEOGENOMICS INC FY ended Feb 13, 2026 | $17.45 | $2.24B | $2.44B | $727.33M | -$35.54M | -$108.03M | -436.25x | 3.08x | — |
OP OPK OPKO HEALTH, INC. FY ended Jan 30, 2026 | $1.52 | $1.13B | $849.37M | $606.88M | -$136.30M | -$225.68M | -5.07x | 1.87x | — |
LH LH LABCORP HOLDINGS INC. FY ended Feb 23, 2026 | $327.61 | $26.57B | $31.51B | $13.95B | $2.00B | $876.50M | 31.32x | 1.90x | 14.29x |
DG DGX QUEST DIAGNOSTICS INC FY ended Feb 02, 2026 | $236.22 | $26.07B | $30.85B | $11.04B | $2.04B | $992.00M | 27.00x | 2.36x | 13.30x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 13.42x | 2/6 | -$1.38B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 8.62x | 6/6 | $28.00B | $146.67 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -107.26x | 6/6 | $22.30B | $116.84 | Peer averages are not economically meaningful for this method. |
